{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"description":"Platelet engraftment is defined as an untransfused platelet measurement \\>20,000/mm3 × 3 consecutive daily assessments. The first of 3 consecutive days for which the untransfused platelet measurement is \\>20,000/mm3 will be recorded as the date of platelet engraftment. Time to platelet engraftment will be calculated as the time from receiving the date of ASCT to the date of platelet engraftment. Untransfused is defined as no transfusions within 7 days.","groups":[{"description":"Granix on Day -7 through Day -2.\n\nHDM intravenously (IV) on Day -2.\n\nAutologous stem cell transplantation on Day 0","id":"OG000","title":"Experimental: Granix and High Dose Melphalan (HDM)"},{"description":"HDM intravenously (IV) on Day -2.","id":"OG001","title":"Control: High Dose Melphalan (HDM)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 participant in control arm did not have a decrease in platelets and is not evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to Day 100","title":"Number of Participants With Platelet Engraftment","type":"SECONDARY","unitOfMeasure":"Participants"}